Private equity has historically run on a reliable hierarchy of value creation: buy well, optimise costs, expand margins, exit at a higher multiple. Revenue growth mattered, but it was rarely the thing the whole investment case depended on. That has changed.
Revenue growth now drives 71% of the value created across European PE deals, up from 45% in 2017, according to Gain’s Private Equity Value Creation Report 2025. Over the same period margin expansion fell from 26% to 12%, and multiple expansion from 29% to 17%. The revenue lever that used to sit in support is now the engine. Yet most mid-market portfolios are still being run for a value creation environment that no longer exists.
A second set of numbers deserves equal attention. Fewer than one in five companies hit their cross-sell targets after an acquisition. Put plainly: acquirers bank most of the cost savings they underwrite, but capture only a quarter to a third of the revenue upside they expect. That gap has not closed in twenty years. For buy-and-build strategies, where cross-sell is often the largest single part of the top-line story, this is the thesis quietly failing.
What separates a 7x exit from a 1.3x exit
Gain’s data shows something that should reframe how every GP thinks about the hold. Top-quartile exits average 7.0x MOIC; bottom-quartile exits average 1.3x. Both rely on revenue growth at almost identical rates, roughly half of the value created in each case. What separates them is multiple expansion: 40% of the uplift in the top quartile, 25% in the bottom.
That 15-point gap is not about who grew revenue faster. It is about whether a buyer believes the growth is organic, structural and repeatable, or whether it was assembled from bolt-ons and a handful of relationships that leave when the people holding them do. The best exits do not sell a revenue number. They sell a commercial model a buyer can trust. Those are very different things, and the distance between them is where value leaks.
Four ways the story erodes
Across mid-market portfolios, we see four failure modes consistently appearing. The first is bolt-on dependence. Inorganic activity flatters the top line while the organic baseline quietly stalls. Experienced buyers strip out acquired revenue and price on the underlying growth rate of the business they are actually buying. Where that rate does not hold up, no amount of last-minute commercial activity recovers the position.
Another apparent mode is pricing drift. Discounts accumulate through deal exceptions and manager discretion: decisions made once that become structural. The gap between list price and realised price across PE-backed portfolios tends to be materially wider than management teams recognise until someone runs the analysis properly. The compounding effect is what makes this damaging – a persistent discount in Year 1 does not just affect Year 1 EBITDA, it establishes a baseline from which organic growth is harder to demonstrate and a margin profile that requires two to three years of disciplined pricing governance to restore. By the time a sale process is under way, there is no time to fix it.
The third is hero dependency. Growth concentrated in two or three individuals is not a commercial model. Buyers understand this and price key-person risk into their offers at exit. The relevant question is not whether the sales leadership is capable, it is whether the commercial system delivers without them. Last is late diagnosis; interventions in Year 4 cannot build the track record buyers need to justify paying a premium. The equity story must be visible and evidenced before a sale process begins, not constructed during it.
It starts at diligence
The cross-sell shortfall is usually blamed on execution: misaligned incentives, weak sales sequencing, poor tracking. Those are real, but they are downstream. Commercial due diligence validates the market and the management team. It rarely tests the machinery underneath: CRM quality, cross-sell propensity at customer level, incentive design. So by day one of the average buy-and-build, you inherit fragmented customer data, sales teams organised around legacy products, no single customer view, and incentives that reward the wrong behaviour.
What changes the outcome is treating commercial readiness as a diligence question, not a post-close clean-up: not the idealised customer profile, list price or headline margin, but the realised ones. Answer those before completion and commercial workstreams become the integration plan itself, rather than a phase-two afterthought.
What good looks like
The businesses that exit in the top quartile are showing buyers a system. Pricing discipline that is governed and evidenced across the hold, not reconstructed for the information memorandum. A customer profile validated against real win-loss data. Pipeline reviewed by cohort and by rep, not in aggregate. Commercial data that reconciles to the audited accounts without a manual workaround. A governance rhythm that holds whether or not the original team is still in the room. This combination is where the re-rating comes from: a 7x exit is a business that grew revenue in a way a buyer can model and verify.
If you are twelve to eighteen months into a hold, you need to be testing whether your revenue baseline is clean, the pricing is governed and the cross-sell is real. Build that now as a system and it compounds into the evidence you sell at exit. Leave it, and you will grow revenue that no buyer pays a premium for.
